Actively Recruiting
Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma
Led by Kazutaka Uchida · Updated on 2025-05-28
600
Participants Needed
1
Research Sites
222 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
COMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle meningeal artery embolization for chronic subdural hematoma.
CONDITIONS
Official Title
Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Pre-mRS score between 0 and 3
- Hematoma thickness of 10 mm or greater
- At least one risk factor including: age 75 or older, antithrombotic therapy, diabetes mellitus, bilateral hematoma, Markwalder grading score greater than 3, preoperative volume 130 ml or greater, preoperative midline shift 8 mm or greater, or specific CT appearances (homogeneous, laminar, or separated)
You will not qualify if you...
- Creatinine level 1.8 or higher
- Platelet count less than 50,000
- PT-INR greater than 2
- Life expectancy less than 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hyogo Medical University
Nishinomiya, Hyōgo, Japan, 663-8501
Actively Recruiting
Research Team
K
Kazutaka Uchida, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here